Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference
Investor & Media Contact: Gabriel Fahel Chief Legal Officer Cybin Inc. 1-866-292-4601 irteam@cybin.com – or – media@cybin.com
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference, on August 12, 2025 in Boston, MA.
Mr. Drysdale's fireside chat will be webcast live on Tuesday, August 12, 2025, at 2:30 p.m. ET. To listen to the event, please click here to access the webcast. The archived webcast will also be available on the Company's investor relations website on the Events & Presentations page.
About Cybin
Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.
Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds.
Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit www.cybin.com or follow the team on X, LinkedIn, YouTube and Instagram.
This story was originally published
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Toronto Star
5 minutes ago
- Toronto Star
Terra Balcanica Closes Fully Subscribed LIFE Offering
Vancouver, British Columbia, Aug. 13, 2025 (GLOBE NEWSWIRE) — Terra Balcanica Resources Corp. ('Terra' or the 'Company') (CSE:TERA; FRA:UB1) is pleased to announce the closing of the second and final tranche of its non-brokered, listed issuer financing exemption private placement (the 'Private Placement' or 'Offering') for gross proceeds of C$302,581 through the issuance of 3,025,809 units (each a 'Unit') at a purchase price of C$0.10 per Unit. Each Unit is comprised of one common share in the capital of the Company ('Common Share') and one-half of one Common Share purchase warrant (each whole warrant, a 'Warrant'). Each Warrant is exercisable to purchase one Common Share ('Warrant Share') at an exercise price of C$0.20 per Warrant Share for a period of 24 months from the closing date of the Private Placement or its respective tranches (the 'Closing Date'). In connection with the final tranche of the Offering, finders' fees in the amount of C$7,000 were paid and 70,000 non-transferable finder's warrants (each, a 'Finder's Warrant') were issued to arm's length finders. Each Finder's Warrant is exercisable for one Common Share at an exercise price of C$0.20 per Common Share for a period of 24 months from the Closing Date. The Company closed an initial tranche of the Offering on July 11, 2025 in the amount of 8,149,141 Units for gross proceeds of C$814,914, as described in the Company's press release dated July 11, 2025. The Company has thus closed on the maximum offering amount of C$1,117,495. Aleksandar Mišković, President and CEO of the Company commented: 'We are very pleased to have raised the full allowable LIFE amount as interest for the offering kept growing by the week. The Phase III drill campaign at Viogor-Zanik in Bosnia is now fully funded and commences imminently. I am on the site to personally oversee the rig turning at Brezani while Terra's team is excited for a robust news release stream to come in the days ahead.'
Cision Canada
5 minutes ago
- Cision Canada
Visionary Holdings Inc. Receives Nasdaq Notification Regarding Late Filing of Form 20-F
TORONTO, Aug. 13, 2025 /CNW/ - Visionary Holdings Inc. (the "Company") (NASDAQ: GV), a private education provider with technology integration, today announced that on August 5, 2025, it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") indicating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) because it has not yet filed its Annual Report on Form 20-F for the fiscal year ended March 31, 2025 (the "Filing") with the Securities and Exchange Commission. Nasdaq's notice has no immediate effect on the listing or trading of the Company's ordinary shares on the Nasdaq Capital Market. However, if the Company fails to timely regain compliance with the Rule, its securities may be subject to delisting from Nasdaq. In accordance with Nasdaq's Listing Rules, the Company has 60 calendar days, or until October 6, 2025, to submit a plan to Nasdaq to regain compliance. If Nasdaq accepts the Company's compliance plan, it may grant the Company an extension of up to 180 calendar days from the Filing's due date, or until January 26, 2026, to file its Form 20-F and regain compliance. The Company is actively working with its independent auditor to complete the audit of its financial statements for the fiscal year ended March 31, 2025, and is preparing its Annual Report on Form 20-F. The Company intends to submit a compliance plan to Nasdaq within the prescribed time period and is committed to regaining compliance as quickly as possible. About Visionary Holdings Inc. Visionary Holdings Inc. is a private education provider located in Canada, with subsidiaries in both the private and public education sectors. The Company aims to provide high-quality, technology-enhanced education services to domestic and international students. Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include the Company's ability to complete and file the Form 20-F within the time required and to regain compliance with Nasdaq's continued listing standards. The Company assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by law.
Globe and Mail
2 hours ago
- Globe and Mail
Sonendo, Inc. Reports Second Quarter 2025 Financial Results and Reaffirms Financial Guidance
Sonendo, Inc. ('Sonendo' or the 'Company'), a leading dental technology company and developer of the GentleWave® System, today reported select financial results for the three-months ended June 30, 2025 and reaffirmed 2025 financial guidance. Select Second Quarter Financial Results Generated $7.4 million of total revenue for the second quarter of 2025, an 11% decline compared to the prior year period, which was expected and driven entirely by lower console sales through a smaller and more cost effective sales team; Reported an increase in gross margin to 41% for the second quarter of 2025, up 320 basis points compared to the prior year period; Reported a $3.6 million reduction in loss from continuing operations compared to the prior period, to $3.9 million for the second quarter of 2025; Drove a 47% year-over-year improvement in Adjusted EBITDA loss to $3.0 million for the second quarter of 2025, driven by focused operational efficiencies; Significantly reduced free cash flow burn to $2.6 million, a 61% reduction compared to the prior year period. 'We are pleased by the continued progress we have made in generating increasing operating leverage in the business, as demonstrated in our second quarter 2025 financial and operational results,' said Bjarne Bergheim, President and Chief Executive Officer of Sonendo. 'In particular, we are selling consoles much more efficiently and with a focus on driving higher procedure instrument utilization. We are also focusing the commercial team's efforts on being more responsive to the clinical needs of our customers and their patients. We recently improved the liquidity profile of the Company in a meaningful way, and we remain steadfastly committed to operational excellence and to position Sonendo for robust, long-term and profitable growth.' As of June 30, 2025, the Company's cash, cash equivalents and short-term investments totaled $9.3 million, and there was $14.2 million of principal outstanding under the Company's credit facility. Financial Guidance The Company is reaffirming the 2025 financial guidance it previously provided, which reflects management's latest expectations and is provided below. (1) See additional information included in the Company's Form 8-K filed with the Securities and Exchange Commission on November 12, 2024 for additional information about the Company's use of these non-GAAP financial measures. About Sonendo Sonendo is a commercial-stage medical technology Company focused on saving teeth from tooth decay, the most prevalent chronic disease globally. Sonendo develops and manufactures the GentleWave® System, an innovative technology platform designed to treat tooth decay by cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure. The system utilizes a proprietary mechanism of action, which combines procedure fluid optimization, broad-spectrum acoustic energy and advanced fluid dynamics, to debride and disinfect deep regions of the complex root canal system in a less invasive procedure that preserves tooth structure. The clinical benefits of the GentleWave System when compared to conventional methods of root canal therapy include improved clinical outcomes, such as superior cleaning that is independent of root canal complexity and tooth anatomy, high and rapid rates of healing and minimal to no post-operative pain. In addition, the GentleWave System can improve the workflow and economics of dental practices. For more information about Sonendo and the GentleWave System, please visit To find a GentleWave doctor in your area, please visit Forward-Looking Statements This news release includes forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the Company's expectations regarding 2025 financial performance, including (among other things) revenue, gross margin, adjusted EBITDA and free cash flow; and the Company's ability to achieve robust, long-term and profitable growth. You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions; speak only as of the date they are made; and, as a result, are subject to risks and uncertainties that may change at any time. Factors that could cause the Company's actual results to differ materially from these forward-looking statements are described in detail in the 'Risk Factors' section of the Company's Annual Report on Form 10-K that was filed with the Securities and Exchange Commission on March 26, 2025. Such filings are available at The Company undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent developments, events, or circumstances, except as may be required under applicable securities laws. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
